Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMVT Immunovant	$15.46 -1.7%	$16.55	$12.72 ▼ $34.47	$2.64B	0.66	1.31 million shs	646,798 shs
KYMR Kymera Therapeutics	$40.62 -0.6%	$45.11	$19.44 ▼ $53.27	$2.65B	2.18	524,846 shs	840,550 shs
RARE Ultragenyx Pharmaceutical	$27.54 -1.0%	$33.32	$25.81 ▼ $60.37	$2.65B	0.25	2.81 million shs	1.53 million shs
TNGX Tango Therapeutics	$6.61	$5.56	$1.03 ▼ $12.02	$735.43M	1.64	1.99 million shs	999,390 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMVT Immunovant	0.00%	-1.59%	-11.66%	+10.27%	-42.70%
KYMR Kymera Therapeutics	0.00%	-5.45%	-10.15%	+35.08%	+0.77%
RARE Ultragenyx Pharmaceutical	0.00%	-3.16%	-11.25%	-21.67%	-43.73%
TNGX Tango Therapeutics	0.00%	+1.23%	+8.18%	+490.18%	-24.20%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMVT Immunovant	1.5312 of 5 stars	3.4	0.0	0.0	2.9	1.7	0.0
KYMR Kymera Therapeutics	3.4604 of 5 stars	4.6	3.0	0.0	2.8	2.5	0.0
RARE Ultragenyx Pharmaceutical	4.3941 of 5 stars	4.5	1.0	3.8	3.0	2.5	0.6
TNGX Tango Therapeutics	1.9648 of 5 stars	3.5	1.0	0.0	3.2	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMVT Immunovant	2.80	Moderate Buy	$35.33	128.55% Upside
KYMR Kymera Therapeutics	3.10	Buy	$59.11	45.52% Upside
RARE Ultragenyx Pharmaceutical	2.92	Moderate Buy	$81.50	195.93% Upside
TNGX Tango Therapeutics	3.00	Buy	$10.33	56.33% Upside

Current Analyst Ratings Breakdown

Latest TNGX, KYMR, RARE, and IMVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	RARE Ultragenyx Pharmaceutical	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$136.00 ➝ $128.00
8/6/2025	RARE Ultragenyx Pharmaceutical	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$112.00 ➝ $105.00
8/6/2025	TNGX Tango Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$8.00 ➝ $10.00
7/30/2025	KYMR Kymera Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$60.00
7/28/2025	IMVT Immunovant	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$17.00 ➝ $18.00
7/28/2025	RARE Ultragenyx Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$80.00
7/15/2025	KYMR Kymera Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/14/2025	RARE Ultragenyx Pharmaceutical	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$35.00 ➝ $34.00
7/14/2025	RARE Ultragenyx Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$65.00 ➝ $55.00
7/10/2025	IMVT Immunovant	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$18.00
7/10/2025	RARE Ultragenyx Pharmaceutical	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$88.00 ➝ $65.00

(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.16 per share	N/A
KYMR Kymera Therapeutics	$47.07M	56.20	N/A	N/A	$12.90 per share	3.15
RARE Ultragenyx Pharmaceutical	$560.23M	4.74	N/A	N/A	$1.57 per share	17.54
TNGX Tango Therapeutics	$42.07M	17.48	N/A	N/A	$1.21 per share	5.46

Compare Profitability & Earnings

Company	Net Income	EPS	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMVT Immunovant	-$413.84M	-$2.74	N/A	N/A	N/A	-80.60%	-71.89%	8/12/2025 (Estimated)
KYMR Kymera Therapeutics	-$223.86M	-$3.10	N/A	N/A	-409.07%	-30.11%	-25.65%	8/11/2025 (Estimated)
RARE Ultragenyx Pharmaceutical	-$569.18M	-$5.53	N/A	N/A	-87.34%	-237.48%	-37.66%	N/A
TNGX Tango Therapeutics	-$130.30M	-$1.33	N/A	N/A	-599.11%	-79.72%	-49.30%	N/A

Latest TNGX, KYMR, RARE, and IMVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q1 2026	IMVT Immunovant	-$0.69	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	KYMR Kymera Therapeutics	-$0.84	N/A	N/A	N/A	$17.37 million	N/A
8/5/2025	Q2 2025	RARE Ultragenyx Pharmaceutical	-$1.27	-$1.17	+$0.10	-$1.17	$161.37 million	$166.50 million
8/5/2025	Q2 2025	TNGX Tango Therapeutics	-$0.35	-$0.35	N/A	-$0.35	$6.41 million	$3.18 million
5/29/2025	Q4 2025	IMVT Immunovant	-$0.72	-$0.64	+$0.08	-$0.64	N/A	$0.16 million
5/12/2025	Q1 2025	TNGX Tango Therapeutics	-$0.34	-$0.36	-$0.02	-$0.36	$6.73 million	$5.39 million
5/9/2025	Q1 2025	KYMR Kymera Therapeutics	-$0.92	-$0.82	+$0.10	-$0.82	$11.38 million	$22.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMVT Immunovant	N/A	11.16	11.16
KYMR Kymera Therapeutics	N/A	8.49	8.49
RARE Ultragenyx Pharmaceutical	N/A	2.45	2.24
TNGX Tango Therapeutics	N/A	4.75	6.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMVT Immunovant	47.08%
KYMR Kymera Therapeutics	N/A
RARE Ultragenyx Pharmaceutical	97.67%
TNGX Tango Therapeutics	78.99%

Insider Ownership

Company	Insider Ownership
IMVT Immunovant	1.80%
KYMR Kymera Therapeutics	16.01%
RARE Ultragenyx Pharmaceutical	5.50%
TNGX Tango Therapeutics	7.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMVT Immunovant	120	171.07 million	167.99 million	Optionable
KYMR Kymera Therapeutics	170	65.12 million	54.69 million	Optionable
RARE Ultragenyx Pharmaceutical	1,294	96.37 million	91.07 million	Optionable
TNGX Tango Therapeutics	90	111.26 million	102.92 million	Optionable

TNGX, KYMR, RARE, and IMVT Headlines

Recent News About These Companies

Cantor Fitzgerald Analysts Lift Earnings Estimates for TNGX

August 9 at 9:27 AM | marketbeat.com

Q3 EPS Estimate for Tango Therapeutics Lifted by Analyst

August 8 at 8:02 AM | marketbeat.com

Wedbush Forecasts Stronger Earnings for Tango Therapeutics

August 8 at 2:15 AM | americanbankingnews.com

Guggenheim Boosts Tango Therapeutics (NASDAQ:TNGX) Price Target to $10.00

August 7 at 11:44 AM | marketbeat.com

Tango (TNGX) Q2 Revenue Drops 52%

August 5, 2025 | fool.com

Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Lags Revenue Estimates

August 5, 2025 | zacks.com

Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

August 5, 2025 | globenewswire.com

Tango Therapeutics (NASDAQ:TNGX) Trading Up 7.1% - What's Next?

August 2, 2025 | marketbeat.com

Wall Street Analysts Believe Tango Therapeutics (TNGX) Could Rally 61.46%: Here's is How to Trade

July 30, 2025 | zacks.com

Tango Therapeutics (TNGX) to Release Quarterly Earnings on Tuesday

July 30, 2025 | marketbeat.com

Tango Therapeutics, Inc. (TNGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

July 29, 2025 | zacks.com

Tango Therapeutics (NASDAQ:TNGX) Shares Up 3% - Should You Buy?

July 24, 2025 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Stock Price Up 9.1% - Time to Buy?

July 18, 2025 | marketbeat.com

TNGX - Tango Therapeutics Inc News - Morningstar

July 16, 2025 | morningstar.comM

Does Tango Therapeutics (TNGX) Have the Potential to Rally 75.89% as Wall Street Analysts Expect?

July 14, 2025 | zacks.com

Tango Therapeutics (NASDAQ:TNGX) Shares Down 4.6% - Time to Sell?

July 11, 2025 | marketbeat.com

Tango Therapeutics doses first patient in cancer drug combo trial

June 29, 2025 | uk.investing.com

Tango Therapeutics Shares Climb After First Patient Dosed in Pancreatic, Lung Cancer Trial

June 27, 2025 | marketwatch.com

Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer

June 27, 2025 | globenewswire.com

Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last? - Nasdaq

June 25, 2025 | nasdaq.com

Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last?

June 23, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Short Squeeze Candidates With Big Catalysts on the Horizon
By Dan Schmidt | July 25, 2025
View 3 Short Squeeze Candidates With Big Catalysts on the Horizon
Why the American Eagle Stock Rally Isn't Just Speculation
By Gabriel Osorio-Mazilli | July 28, 2025
View Why the American Eagle Stock Rally Isn't Just Speculation
These 3 Rare Earth Stocks Are Surging Alongside MP Materials
By Leo Miller | July 19, 2025
View These 3 Rare Earth Stocks Are Surging Alongside MP Materials
NVIDIA: A Major Indicator Just Flashed Sell, But Should You?
By Sam Quirke | July 30, 2025
View NVIDIA: A Major Indicator Just Flashed Sell, But Should You?
MP Materials Stock Booms on New Government Positioning
By Gabriel Osorio-Mazilli | July 14, 2025
View MP Materials Stock Booms on New Government Positioning

TNGX, KYMR, RARE, and IMVT Company Descriptions

Immunovant NASDAQ:IMVT

$15.46 -0.27 (-1.72%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$16.32 +0.86 (+5.56%)

As of 08/8/2025 07:35 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Kymera Therapeutics NASDAQ:KYMR

$40.62 -0.23 (-0.56%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$40.62 +0.01 (+0.01%)

As of 08/8/2025 04:14 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Ultragenyx Pharmaceutical NASDAQ:RARE

$27.54 -0.29 (-1.04%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$27.56 +0.02 (+0.05%)

As of 08/8/2025 05:21 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Tango Therapeutics NASDAQ:TNGX

$6.61 0.00 (0.00%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$6.62 +0.01 (+0.15%)

As of 08/8/2025 07:32 PM Eastern

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time